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Abstract
About 20% of the general population is contact-sensitized to common
haptens such as fragrances, preservatives, and metals. Many also develop
allergic contact dermatitis (ACD), the clinical manifestation of contact
sensitization. ACD represents a common health issue and is also one of the
most important occupational diseases. Although this inflammatory skin
disease is mediated predominantly by memory T lymphocytes recognizing
low-molecular-weight chemicals after skin contact, the innate immune
system also plays an important role. Along that line, the presence of irritants
may increase the risk of ACD and therefore ACD is often seen in the
context of irritant contact dermatitis. In this review article, we discuss recent
progress in basic research that has dramatically increased our
understanding of the pathomechanisms of ACD and provides a basis for
the development of novel diagnostic and therapeutic measures. Current
methods for diagnosis as well as treatment options of ACD are also
discussed.
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Introduction
Allergic contact dermatitis (ACD) is an inflammatory skin 
disease that affects about 20% of the adult general population 
and is also an important occupational skin disease1–3. A recent 
study showed that 27% of the general population from five 
European countries had contact allergy (that is, sensitization to 
at least one contact allergen of the European baseline series)4. 
A large proportion of these individuals are at risk of develop-
ing ACD following exposure to everyday products. Among 
the occupational diseases, 40% are skin-related5. Contact 
dermatitis (both irritant and allergic) accounts for about 90% 
of these. Collectively, these epidemiological data demonstrate 
the importance of ACD as a challenge to human health. There-
fore, basic and clinical research is needed to understand the 
pathomechanisms of ACD and to develop better strategies for 
diagnosis and treatment.
ACD is mediated by T cells recognizing low-molecular-
weight organic chemicals or metal ions in the context of major 
histocompatibility complex (MHC) molecules6. These usually 
electrophilic chemicals penetrate the skin and react with extra-
cellular and cellular proteins. Their protein reactivity is manda-
tory and underlies their unusual ability to trigger innate immune 
as well as T-cell responses7–9. Activation of the innate immune 
system is a prerequisite for the activation and skin migration 
of contact allergen-specific T cells. The first skin contact with 
allergens initiates the activation of skin cells, most importantly the 
epidermal Langerhans cells and dermal dendritic cells (DCs), 
which subsequently migrate to the local lymph nodes and 
present the contact allergen(s) to naïve T cells. Contact 
allergen-specific T cells then proliferate and differentiate to 
effector T cells that enter the blood circulation. Repeated skin 
contact with the same contact allergen then results in the recruit-
ment of these T cells into the skin and the elicitation of the 
clinical reaction of ACD (Figure 1). The response is limited 
and downregulated by regulatory T and B cells, natural killer T 
(NKT) cells, and further cell types9. Here, we review recent 
progress in basic research aimed at understanding the cellular 
and molecular mechanisms underlying the innate immune 
responses as well as the pathogenic T-cell response and its 
regulation. Moreover, we will give an overview of the current 
status of the management of ACD in the clinic.
Protein reactivity of contact allergens
The central role of the protein modification by contact allergens 
is underlined by the fact that two of the three validated in vitro 
assays for the identification of contact allergens are based 
on protein reactivity. The Direct Peptide Reactivity Assay— 
Organisation for Economic Co-operation and Development 
(OECD) test guideline TG 442C—detects the depletion of 
model peptides containing modifiable lysine or cysteine residues. 
Electrophilic chemicals binding covalently to the ε-amino group 
of lysine or the thiol (SH) group of cysteine are classified as 
potential contact allergens. Similarly, covalent modification of 
cysteine residues in the cytosolic protein Keap1 and the subse-
quent release and DNA binding of the transcription factor Nrf2 
lead to the activation of luciferase in HaCaT keratinocytes in the 
ARE-Nrf2 Luciferase Test Method (OECD test guideline TG 
Figure 1. Sensitization phase of allergic contact dermatitis. Contact allergens penetrate the skin and cause tissue stress and damage. 
Reactive oxygen species (ROS) are formed, ATP is released from stressed cells, and damage-associated molecular patterns (DAMPs) are 
formed/released from cells. DAMPs then trigger activation of the innate immune system via Toll-like receptors (TLRs) and NOD-like receptor 
pyrin containing 3 (NLRP3). This results in skin inflammation and consequently activation of dendritic cells (DCs) and migration to the 
skin-draining lymph nodes. DCs present contact allergens to naïve T cells, leading to their activation and effector cell differentiation. This 
concludes the sensitization phase. In the elicitation phase, repeated skin contact with the same contact allergen induces inflammation, and 
T cells are recruited into the inflamed skin, where they exert their effector functions, leading to clinical symptoms of allergic contact dermatitis. 
MHC, major histocompatibility complex; PRR, pattern recognition receptor.
Page 3 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
442D)10. The Keap1/Nrf2 pathway is central in the antioxidant 
phase 2 response.
One of the most challenging research questions is the identifica-
tion of (a) the target proteins that, upon hapten modification, 
lead to activation of the innate immune system and cellular stress 
responses and (b) the natural T-cell epitopes generated after 
protein modification. Until now, the few known physiologically 
relevant protein targets of contact allergens have been identified 
in cell lines. Recent studies addressing these questions in vivo 
have identified keratins in mouse skin after topical application of 
bromobimanes11 and the macrophage migration inhibition factor 
(MIF) in skin-draining lymph nodes after topical application 
of tetramethylrhodamine isothiocyanate (TRITC)12 as protein 
targets for hapten modification. It is still not known whether 
these hapten modifications alter the function of the proteins 
or generate T-cell epitopes. In the case of MIF, an N-terminal 
proline modification was detected, but potential effects on the 
function of MIF were not investigated.
Role of mast cells and neutrophils in contact 
hypersensitivity
Skin inflammation is essential in the sensitization and 
elicitation phase of ACD. Its initiation requires the close 
cooperation of different cell types, which together orchestrate 
this complex response (Figure 1). It was recently demonstrated 
that mast cells are important innate effector cells in murine 
contact hypersensitivity (CHS), the mouse model for ACD13. 
CHS was significantly reduced in mast cell-deficient or -
depleted mice. The reasons for that were the lack of neutrophil 
extravasation into inflamed skin initiated by the localization 
of mast cells in proximity of blood vessels and by secretion of 
the pre-formed and de novo synthesized neutrophil-attracting 
chemokines CXCL1/CXCL2 as shown in a lipopolysaccharide- 
induced peritonitis model. Interestingly, macrophages were 
required for deeper neutrophil migration into the tissue14. 
Granule release and de novo chemokine synthesis were 
Toll-like receptor 4 (TLR4)-dependent. DC emigration from the 
skin was compromised by the selective absence of mast cells or 
neutrophils, as was T-cell recruitment to the skin13–15.
A very interesting study in a model of chronic CHS showed 
that mast cells can also limit CHS16. Using mast cell-deficient 
Sash or mast cell-depleted Mcpt5-Cre diphtheria toxin receptor 
(DTR) mice, the authors showed a significant increase of the ear 
swelling reaction in mast cell-deficient mice which was depend-
ent on CD8+ tissue-resident memory T (TRM) cells. The effect 
correlated with elevated levels of interleukin (IL)-15 needed for 
cutaneous TRM cells. Thus, in this chronic CHS model, mast 
cells limited the CD8+ TRM cell response by degrading IL-15 via 
proteases such as chymase and carboxypeptidase A.
Role of tissue-resident T cells and γδ T cells in 
contact hypersensitivity
In general, TRM cells form local memory in tissues and are 
responsible for rapid and strong reactions upon re-exposure to a 
contact allergen. It was shown that TRM cells are generated from 
the same naïve precursor as central memory T (TCM) cells in the 
skin-draining lymph nodes. They seed the contact allergen- 
exposed skin sites, reside there, and produce a rapid allergic 
response upon re-exposure17. Schmidt et al. identified IL-17- and 
interferon-gamma (IFN-γ)-producing CD8+ TRM cells in the 
2,4-dinitrofluorobenzene (DNFB) CHS mouse model18. The 
generation of local memory due to TRM cells was shown for both 
mice and nickel-allergic humans.
It was recently reported in the CHS model that dendritic 
epidermal T cells (DETCs), which are not found in human 
skin, rapidly produced IL-17 in response to contact allergens19. 
However, how these cells were activated was unclear. Nielsen 
et al. revealed that the activating natural killer (NK) receptor 
NKG2D is involved in their activation20. NKG2D was found 
to be expressed on most DETCs and in human CLA+ γδ T cells. 
Mouse keratinocytes upregulated various stress-induced NKG2D 
ligands when exposed to contact allergens in vitro. Moreover, in 
the mouse system, the NKG2D ligand Mult1 was upregulated 
by contact allergens in the skin. Experiments with anti-NKG2D 
blocking antibodies showed a partial block in the activation 
of DETCs. This study suggests a contact allergen-induced 
interaction of epidermal γδ T cells with keratinocytes which 
results in an IL-1β-driven and NKG2D/NKG2DL-dependent 
T-cell activation and production of IFN-γ and IL-17. This may 
be part of the early antigen non-specific innate inflammatory 
response to contact allergens. Jiang et al. recently reported a role 
for dermal γδ T cells in promoting CHS by IL-17-dependent 
neutrophil recruitment17. They identified a population of γδ 
T cells which had characteristics of tissue-resident cells with low 
re-circulation potential. These dermal γδ T cells produced IL-17 
and IL-22. Importantly, DNFB-induced CHS was significantly 
reduced in mice selectively lacking dermal γδ T cells but not 
DETCs. The authors showed that this was due to reduced 
neutrophil recruitment. This study underlines the important role 
of neutrophils in CHS15.
Much progress has been made in the field of metal allergies. 
Since nickel and cobalt were identified as the first contact aller-
gens able to directly activate a pattern recognition receptor (that 
is, human TLR4 by inducing its dimerization and signaling21–23), 
it was shown that nickel also activates the NLRP3 (NOD-
like receptor pyrin containing 3) inflammasome24. Likewise, 
chromium VI, but not chromium III, compounds activate the 
NLRP3 inflammasome25. However, chromium fails to provide 
a priming signal, such as TLR4 activation in the case of nickel, 
which is needed for inflammasome activation. This was shown 
in vitro, and the findings are reminiscent of contact allergens 
such as 2,4,6-trinitrofluorobenzene (TNCB) and oxazolone 
which also fail to do that in vitro26,27. In that case, a tissue-derived 
priming signal was generated by induction of hyaluronic acid 
breakdown27. Thus, it may well be that chromium also has to 
induce a tissue-derived priming signal.
Recently, TLR3 was shown to modulate CHS responses in mice. 
Both irritant contact dermatitis (ICD) (croton oil) as well as 
ACD (TNCB) were reduced in the absence of TLR3 in 
knockout (KO) mice and increased in TLR3-overexpressing 
mice28. For ACD to TNCB, a role for TLR3 was confined to the 
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elicitation phase. The mechanism of TLR3 activation was not 
identified, but the authors speculated on the release of self-RNA 
from necrotic skin cells. It must also be considered that TLR3 
ligands may derive from the bacterial skin flora. Experiments 
in germ-free mice would be needed to clarify that. Up to now, 
CHS experiments in germ-free mice have indicated that the 
innate immune system activation can be triggered by contact 
allergens in the absence of a microbial flora26,27.
In general, the data published up to now for organic chemical 
allergens and metal allergens in humans and mice reveal 
a common mechanistic innate immune response pathway. 
Contact allergens generate tissue-derived activators of TLRs 
or are themselves direct activators. Following TLR activation, 
pro-inflammatory mediators, among them pro-IL-1β, a central 
cytokine in ACD, are produced. The NLRP3 inflammasome 
is then activated by different means depending on the contact 
allergen. Oxidative stress that promotes inflammation is induced 
(Figure 1). In general, TLR triggering and inflammasome 
activation are essential steps in the innate immune response and 
the mechanisms underlying their activation present as variations 
of a common theme. It remains to be determined how general this 
theme is given the high number and physicochemical diversity 
of the more than 4,000 contact allergens known today.
Skin inflammation can also be induced by irritant chemicals 
such as detergents like sodium dodecyl sulfate (SDS). This is 
due in part to a damaging effect on the skin barrier. Therefore, a 
combination of irritants and contact allergens as often found in 
cosmetics, household products, and workplace materials can facili-
tate sensitization due to the amplification of skin inflammation 
resulting in, for example, the augmentation of DC activation29. 
Moreover, combinations of contact allergens show similar 
augmentation due to additive or synergistic effects of the so-
called irritant effects of contact allergens (that is, their ability to 
activate the innate immune system)9,30–32.
Genomics and proteomics
The identification of biomarkers would be very helpful in 
improving diagnostics and treatment of ACD33. Dhingra et al. 
performed gene array studies using skin samples from patch 
test biopsies34. Besides identifying 149 genes that were differ-
entially expressed in all contact allergen-treated samples, they 
identified a significant number of genes that were regulated in a 
contact allergen-specific manner. This study nicely shows that the 
clinical appearance of ACD can be very similar for different 
contact allergens but that the underlying immune responses can be 
very different as highlighted here for the polarization of the T-cell 
response.
Quaranta et al. compared different forms of eczema (atopic and 
non-atopic) regarding gene expression profiles35. They made use 
of an interesting study population: patients with both psoriasis 
and eczema. In addition, some of these patients developed 
ACD when tested with nickel. This study allowed an 
inter-individual comparison of different types of eczema which 
could be differentiated on the basis of their characteristic gene 
expression. Comparing naturally occurring eczema with 
nickel-induced eczema revealed that 33 genes were commonly 
regulated but that 172 genes were exclusively regulated in 
induced and 28 exclusively in naturally occurring eczema. 
Pathway analysis revealed marked differences in genes regulating 
epithelial differentiation, extracellular matrix, cell–cell adhesion, 
and the acute immune response. Examples for ACD-specific 
genes were genes for T-cell attraction (CXCL9, 10, and 11) 
that had already been described as discriminators for ACD36,37, 
LCE1 and LCE2 family genes, and HAS3, EPSTI1, ICAM-1, 
CXCL8, IL-1β, and AIM2. Interestingly, detailed data analysis 
led the authors to claim a two-gene classifier (NOS2 and CCL27) 
for the distinction between psoriasis and atopic dermatitis38.
Besides analysis of gene expression, proteomics are being 
used to identify contact allergen-induced changes in protein 
profiles. Using matrix-assisted laser desorption/ionization-mass 
spectrometry analysis, Jakob et al. showed that Ni2+ treatment 
of human CD14+ monocytes isolated from peripheral blood 
mononuclear cells significantly altered the expression of 56 
protein species39. Further analysis revealed the induction of 
proteins associated with apoptotic cell death at concentrations of 
around 250 µM and above, concentrations which did not affect 
T-cell viability. Interestingly, Schmidt et al. had previously 
shown a sensitization of human umbilical vein endothelial cells 
for TRAIL (tumor necrosis factor-related apoptosis-inducing 
ligand)-induced cell death by nickel40.
Mussotter et al. compared the protein profiles of bone marrow-
derived dendritic cells (BMDCs) from C57BL/6 wild-type and 
Nrf2-deficient mice41. More than 50 proteins were upregulated 
upon BMDC treatment with cinnamic aldehyde and more than 
30 upon 2,4-dinitrochlorobenzene (DNCB) treatment. Notably, 
almost all of these proteins were not upregulated in BMDCs from 
Nrf2-deficient mice. Nrf2-dependent proteins were associated 
with oxidative stress, cell survival/death, proteostasis, and other 
signaling pathways. In addition, metabolic reprogramming by 
contact sensitizers was revealed (for example, by upregulation of 
many glycolytic enzymes). This approach allows identification of 
Nrf2-dependent and -independent proteins and differentiation 
between contact sensitizer- and irritant-specific effects.
More recent profiling studies of patients with ACD used 
serum42 samples from stratum corneum after tape stripping43, skin 
biopsies44,45, or monocytes36. Analyses were carried out by protein 
or gene arrays and mass spectrometry. Owing to the diversity of 
the samples, the different contact allergens used, and the differ-
ent methods used, it is impossible to compare the data and search 
for common biomarkers. Nevertheless, inflammation and skin 
barrier-related genes and proteins are, not surprisingly, 
differentially regulated in all studies. The big challenge is the 
identification of biomarker profiles that allow differentiation 
between ACD and ICD and between ACD and other forms of 
eczema.
More such genomic and proteomic studies are needed to 
understand how contact sensitizers work on a mechanistic basis. 
Novel biomarkers can be identified that may aid in the improve-
ment of ACD diagnostics, identification of novel drug targets, and 
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in vitro assay development for contact allergen identification and 
replacement of animal testing.
Immune regulation and tolerance to contact allergens
Regulatory T cells (Tregs) are central regulators of the extent and 
duration of CHS responses. The important role of Tregs in CHS 
has been underlined by a recent study using CD103-deficient 
KO mice46. The integrin αE (CD103) is expressed on subsets of 
DCs and on Tregs localizing to epithelia. CHS to oxazolone or 
DNCB was significantly increased in the KO mice. The authors 
then found that the level of Foxp3 was significantly reduced 
in CD4+CD25+ T cells and that Tregs from the KO mice were 
unable to suppress CHS. This study shows that CD103 has a role 
in the regulation of Foxp3 expression in addition to its function 
of retention of Tregs in inflamed skin.
Tregs express the ectonucleotidases CD73 and CD39, which 
degrade ATP to tolerogenic adenosine47. It has been shown 
that one consequence of this is the retention of CD8+ effector 
T cells in the lymph nodes. Mahnke et al. showed that CD8+ 
T cells shed CD62L in order to leave the lymph node, a process 
required for effector cell migration to inflamed skin in CHS48. 
ATP is released from skin cells following contact allergen 
application49. In T cells, ATP acts on P2X7R to upregulate 
ADAM17 which sheds CD62L from the T-cell surface. Moreo-
ver, CD73-dependent ATP degradation seems to limit the extent 
of DC emigration from skin and eventually the magnitude of 
CHS50.
Interestingly, similar to observations in viral infections51,52, 
IL-10-producing CD8+ T cells can be detected in the late 
elicitation phase of CHS53. Although in respiratory syncytial 
virus lung infection an autocrine regulatory role of these effec-
tor cells has been shown52, in the CHS model this could not be 
confirmed. Nevertheless, one may speculate that the CD8+ CHS 
effector T cells start to express IL-10 later in the elicitation 
phase and contribute to the limitation of the extent and the 
downregulation of the CHS response.
The previously reported roles of NKT cells and regulatory 
B cells (Bregs) in CHS were supported by Fjelbye et al.54. These 
authors showed increased CHS responses in CD1d-deficient 
mice. This was mostly due to a decrease of IL-10 and a predomi-
nant reduction in IL-10+ Bregs in the spleen and peritoneal cavity. 
These data strongly suggest a regulation of Bregs by CD1d-
restricted NKT cells, which have been identified as an important 
regulatory cell type in CHS55.
Tolerance to contact allergens can be induced experimen-
tally by different means. Low zone tolerance (LZT) is induced 
by the repeated epicutaneous application of doses of contact 
allergens 100- to 1,000-fold lower than the dose used for sen-
sitization. LZT involves IL-10-producing Foxp3+ Tregs which 
induce tolerogenic CD8+CD11c+ DCs and is most likely caused 
by the presentation of contact allergen to T cells in the absence 
of skin inflammation56. Another way of tolerance induction is oral 
tolerance. Hacini-Rachinel et al. showed that oral tolerance to 
DNFB given to mice by gavage was dependent on TLR4 
expression on hematopoietic cells57. They demonstrated that 
TLR4 is necessary to induce the mobilization of tolerogenic 
CD103+CD11c+ lamina propria DCs to migrate to the local lymph 
nodes and prime Foxp3+ Tregs. Complexes of IL-2/anti-IL-2 
antibodies have been shown to enhance IL-2 effects and are 
considered to treat inflammatory diseases on the basis of their 
expansion of Tregs. El Beidaq et al. demonstrated that tolerance 
to CHS mediated by TNCB can be enforced by injection of an 
IL-2/anti-IL-2 antibody reagent, IL-2/JES6-158. This treatment, 
when given before or even after sensitization, established a state 
of tolerance by CTLA4+Foxp3+ Treg expansion that was still 
evident upon re-challenge with contact allergen even 3 weeks 
after the last injection. IL-10 and transforming growth factor-
beta (TGF-β) levels were increased while neutrophil and CD8+ 
T-cell infiltration of the skin were reduced. This study is encour-
aging, since it shows that a longer-lasting re-establishment of 
tolerance to contact allergens is possible. The issue of estab-
lishing directed, antigen-specific tolerance needs to be solved. 
However, in a double-blinded, placebo-controlled study, Di 
Gioacchino et al. demonstrated the re-establishment of toler-
ance to nickel by oral hyposensitization59. A total of 113 patch 
test-positive patients with systemic nickel syndrome due to 
nickel-containing foods were given nickel orally for 1 year. Re-
introduction of nickel-rich food revealed significant improve-
ment of gastrointestinal symptoms. Skin manifestations also 
improved, but significance was not reached. On the other end of 
the spectrum, oral or systemic exposure to contact allergens in 
sensitized individuals may result in systemic contact dermatitis, 
a skin reaction characterized by flexural and inverse involvement 
of eczema. This may occur following high-dose nickel expo-
sure in very nickel-sensitized individuals but also following oral 
exposure to sesquiterpene lactone allergens (for example, chamo-
mile in tea) in plant-allergic individuals. Other examples include 
systemic contact dermatitis reactions in patients with an allergy 
to Myroxylon pereirae resin (balsam of Peru) who eat citrus 
fruits.
Diagnostics in clinical allergic contact dermatitis
From the clinical point of view, ACD has hardly any specific 
appearance, although vesicular morphology is frequent and ACD 
as opposed to ICD characteristically spreads and generalizes if the 
allergen is not removed. In general, ACD results in an eczematous 
reaction of the skin, although non-eczematous reactions such as 
lichenoid reactions and implant failure have also been reported 
in contact-allergic individuals. This lack of highly specific clini-
cal characteristics indicates the need and benefit of reproducible 
diagnostic procedures. Since the beginning of clinical contact 
allergy diagnosis with Jadassohn in 1895, epicutaneous applica-
tion of suspected contact allergens has been the diagnostic method 
of choice. The general principle is unchanged since then: contact 
allergens are dissolved in adequate vehicles such as water, alco-
hol, and petrolatum, allowing the allergens to penetrate out of the 
preparation into the epidermis. For most allergens, the highest 
non-irritating allergen concentrations are optimal60. Classic 
exceptions are glucocorticosteroids: too high a concentration 
causes immunosuppression rather than eliciting allergic reactions, 
although characteristic dermatitis is formed in a ring surround-
ing the chamber which contains the glucocorticosteroid. For 
glucocorticosteroids, optimal test concentrations are established 
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on the basis of a more sophisticated balance of sufficient allergen 
to elicit the allergic reaction and too little to suppress it61. All test 
preparations for contact allergens are optimized for epicutaneous 
application, mostly under occlusion, for 48 hours. Patient prod-
ucts may also be applied directly (for example, a piece of a glove 
or shoe, a metallic disc, nail lacquer, or scrapping from specta-
cle frames in a chamber). Allergen preparations are kept in place 
by using adhesive materials with small allergen chambers. The 
chambers are made from either aluminum or polypropylene 
and in some products with an inlay from filter paper. The total 
amount of allergen preparation for one chamber depends on the 
chamber size. For most of the commercial patch test chambers, 
15–20 µL of allergen preparation suffices. Application of too 
high a volume can result in spoiling out of the test chamber and 
false-positive patch test reactions. Some allergens are volatile 
and might evaporate from the patch test material (for example, 
fragrance chemicals)62. This can occur during the preparation of 
the patch tests for one patient. Hence, test materials should be 
prepared directly before application onto the skin. The evapo-
ration process starts for highly volatile allergens directly with 
manufacturing the test materials. For these allergens, transport 
and storage in fridges or freezers (especially for isocyanate 
allergens) are advisable.
In most patients, patch tests are applied onto the back of the 
patient. After 48 hours of application, patches are removed and 
test sites are read in accordance with the current guideline63. The 
readings have to be performed at at least two different time 
points. Common reading schedules are 48 hours, 72 hours, and 
6–7 days. But reading schedules skipping the first reading and 
including a 96-hour reading are practiced64. The reading of 
test readings is independent from interpretation of the results, 
which should be performed subsequently65. Exposure analysis is 
important before clinical relevance of positive test reactions 
is decided. Positive test reactions are grouped into current, 
past, and unknown clinical relevance on the basis of allergen 
exposure, patient history, and the clinical pattern.
Current and future treatment options
In the case of clinically relevant ACD, the disease resolves if 
the patient avoids future skin exposure to the culprit allergen. 
Thorough information about sources of allergen exposure is 
crucial, as is instruction about how to read ingredient labels and 
use spot tests for metal ion release. However, time from avoid-
ance of allergen exposure to complete resolution can take months 
in the case of severe disease but in milder cases may occur 
within a few weeks. Topical application of emollients along with 
anti-inflammatory agents (for example, calcineurin inhibitors 
and corticosteroids) is first-line treatment and typically will 
rapidly heal the lesions. However, ACD often occurs in the 
context of other eczematous conditions, including ICD or atopic 
dermatitis. In these cases, patients may have a more chronic 
disease and resolution cannot be obtained through allergen 
avoidance alone. Here, ultraviolet irradiation or systemic 
immunosuppressants such as methotrexate, cyclosporine, and 
azathioprine may be necessary to control inflammation. This is 
often the case in patients with chronic hand eczema. Systemic 
corticosteroids should generally be avoided in patients with 
chronic dermatitis because of the risk of severe complication such 
as osteoporosis and type 2 diabetes but may be very useful in 
patients with acute severe ACD following exposure to, for 
example, poison ivy or para-phenylenediamine (PPD). So far, 
no biologics have been proven to be useful in the treatment of 
ACD, although only case series have been performed66. Based on 
the successful experience of patch testing patients who receive 
various biologics and immunosuppressants, none of these seems 
to really suppress ACD and therefore they are not suitable for 
treating ACD per se67. So far, oral tolerance induction has 
not been successful, but a randomized Italian study showed 
that an improvement of gastrointestinal symptoms follow-
ing oral nickel exposure by food and a significant increase in 
patch test negativity may be obtained59. At the moment, it is 
impossible to envision any drugs that may directly inhibit ACD 
responses in affected patients, but it is possible that the innate 
immune system needs to be targeted at an early stage to prevent 
the cascade of reactions in chronic disease9.
Given the complexity of ACD, a multi-layered strategy for 
treatment seems necessary. Interference with mechanisms of 
inflammation, enforcement of immune regulation, and reduction, 
removal, or suppression of effector and memory T cells, 
including TRM cells, are areas to be exploited in the future. Based 
on our increasing understanding of the pathomechanisms, com-
bination therapies may have to be developed for acute and 
hard-to-treat chronic ACD. The ongoing search for biomarkers 
will hopefully lead to the identification of profiles suitable for 
modern molecular diagnostics. New in vitro assays should be 
suitable to identify contact allergens for hazard identification10. 
Here, assays that allow potency assessment of contact allergens 
are urgently needed.
The ongoing basic and clinical research as well as in vitro test-
ing for contact allergen identification, the recognition of the 
impact of contact dermatitis, and the continuing education and 
training to raise awareness for prevention and for improvement of 
workplaces5 will result in avoidance of hazardous chemicals and 
improved management of this important skin disease.
Abbreviations
ACD, allergic contact dermatitis; BMDC, bone marrow-derived 
dendritic cell; Breg, regulatory B cell; CHS, contact hypersen-
sitivity; DC, dendritic cell; DETC, dendritic epidermal T cell; 
DNCB, 2,4-dinitrochlorobenzene; DNFB, 2,4-dinitrofluoroben-
zene; ICD, irritant contact dermatitis; IFN-γ, interferon-gamma; 
IL, interleukin; KO, knockout; LZT, low zone tolerance; MIF, 
macrophage migration inhibition factor; NK, natural killer; 
NKT, natural killer T; NLRP3, NOD-like receptor pyrin 
containing 3; OECD, Organisation for Economic Co-operation 
and Development; TLR, Toll-like receptor; TNCB, 2,4,6-trini-
trofluorobenzene; Treg, regulatory T cell; TRM, tissue-resident 
memory T
Competing interests
The authors declare that they have no competing interests.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
Page 7 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
1. Peiser M, Tralau T, Heidler J, et al.: Allergic contact dermatitis: epidemiology, 
molecular mechanisms, in vitro methods and regulatory aspects. Current 
knowledge assembled at an international workshop at BfR, Germany. Cell Mol 
Life Sci. 2012; 69(5): 763–81.  
PubMed Abstract | Publisher Full Text | Free Full Text 
2. Ring J: Occupational skin disease - a major health problem in Europe. J Eur 
Acad Dermatol Venereol. 2017; 31(6): 919–20.  
PubMed Abstract | Publisher Full Text 
3. Thyssen JP, Linneberg A, Menné T, et al.: The epidemiology of contact allergy in 
the general population--prevalence and main findings. Contact Dermatitis. 2007; 
57(5): 287–99.  
PubMed Abstract | Publisher Full Text 
4.  Diepgen TL, Ofenloch RF, Bruze M, et al.: Prevalence of contact allergy in 
the general population in different European regions. Br J Dermatol. 2016; 
174(2): 319–29.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
5. Alfonso JH, Bauer A, Bensefa-Colas L, et al.: Minimum standards on prevention, 
diagnosis and treatment of occupational and work-related skin diseases in 
Europe - position paper of the COST Action StanDerm (TD 1206). J Eur Acad 
Dermatol Venereol. 2017; 31Suppl 4: 31–43.  
PubMed Abstract | Publisher Full Text 
6. Martin SF, Esser PR, Schmucker S, et al.: T-cell recognition of chemicals, protein 
allergens and drugs: towards the development of in vitro assays. Cell Mol Life 
Sci. 2010; 67(24): 4171–84.  
PubMed Abstract | Publisher Full Text 
7. Kaplan DH, Igyártó BZ, Gaspari AA: Early immune events in the induction of 
allergic contact dermatitis. Nat Rev Immunol. 2012; 12(2): 114–24.  
PubMed Abstract | Publisher Full Text | Free Full Text 
8. Martin SF: Contact dermatitis: from pathomechanisms to immunotoxicology. 
Exp Dermatol. 2012; 21(5): 382–9.  
PubMed Abstract | Publisher Full Text 
9. Martin SF: New concepts in cutaneous allergy. Contact Dermatitis. 2015; 72(1): 
2–10.  
PubMed Abstract | Publisher Full Text 
10. Ezendam J, Braakhuis HM, Vandebriel RJ: State of the art in non-animal 
approaches for skin sensitization testing: from individual test methods 
towards testing strategies. Arch Toxicol. 2016; 90(12): 2861–83.  
PubMed Abstract | Publisher Full Text 
11. Simonsson C, Andersson SI, Stenfeldt A, et al.: Caged fluorescent haptens 
reveal the generation of cryptic epitopes in allergic contact dermatitis. J Invest 
Dermatol. 2011; 131(7): 1486–93.  
PubMed Abstract | Publisher Full Text 
12.  Karlsson I, Samuelsson K, Simonsson C, et al.: The Fate of a Hapten - From 
the Skin to Modification of Macrophage Migration Inhibitory Factor (MIF) in 
Lymph Nodes. Sci Rep. 2018; 8(1): 2895.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
13.  Dudeck A, Dudeck J, Scholten J, et al.: Mast cells are key promoters of 
contact allergy that mediate the adjuvant effects of haptens. Immunity. 2011; 
34(6): 973–84.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
14. De Filippo K, Dudeck A, Hasenberg M, et al.: Mast cell and macrophage 
chemokines CXCL1/CXCL2 control the early stage of neutrophil recruitment 
during tissue inflammation. Blood. 2013; 121(24): 4930–7.  
PubMed Abstract | Publisher Full Text 
15. Weber FC, Németh T, Csepregi JZ, et al.: Neutrophils are required for both the 
sensitization and elicitation phase of contact hypersensitivity. J Exp Med. 
2015; 212(1): 15–22.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16.  Gimenez-Rivera VA, Siebenhaar F, Zimmermann C, et al.: Mast Cells Limit 
the Exacerbation of Chronic Allergic Contact Dermatitis in Response to 
Repeated Allergen Exposure. J Immunol. 2016; 197(11): 4240–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
17.  Jiang X, Park CO, Geddes Sweeney J, et al.: Dermal γδ T Cells Do Not Freely 
Re-Circulate Out of Skin and Produce IL-17 to Promote Neutrophil Infiltration 
during Primary Contact Hypersensitivity. PLoS One. 2017; 12(1): e0169397.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
18.  Schmidt JD, Ahlström MG, Johansen JD, et al.: Rapid allergen-induced 
interleukin-17 and interferon-γ secretion by skin-resident memory CD8+ T 
cells. Contact Dermatitis. 2017; 76(4): 218–27.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
19.  Nielsen MM, Lovato P, MacLeod AS, et al.: IL-1β-dependent activation of 
dendritic epidermal T cells in contact hypersensitivity. J Immunol. 2014; 192(7): 
2975–83.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
20.  Nielsen MM, Dyring-Andersen B, Schmidt JD, et al.: NKG2D-dependent 
activation of dendritic epidermal T cells in contact hypersensitivity. J Invest 
Dermatol. 2015; 135(5): 1311–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
21.  Schmidt M, Raghavan B, Müller V, et al.: Crucial role for human Toll-like 
receptor 4 in the development of contact allergy to nickel. Nat Immunol. 2010; 
11(9): 814–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
22. Raghavan B, Martin SF, Esser PR, et al.: Metal allergens nickel and cobalt 
facilitate TLR4 homodimerization independently of MD2. EMBO Rep. 2012; 
13(12): 1109–15.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Rachmawati D, Bontkes HJ, Verstege MI, et al.: Transition metal sensing by 
Toll-like receptor-4: next to nickel, cobalt and palladium are potent human 
dendritic cell stimulators. Contact Dermatitis. 2013; 68(6): 331–8.  
PubMed Abstract | Publisher Full Text 
24.  Li X, Zhong F: Nickel induces interleukin-1β secretion via the NLRP3-ASC-
caspase-1 pathway. Inflammation. 2014; 37(2): 457–66.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
25. Adam C, Wohlfarth J, Haußmann M, et al.: Allergy-Inducing Chromium 
Compounds Trigger Potent Innate Immune Stimulation Via ROS-Dependent 
Inflammasome Activation. J Invest Dermatol. 2017; 137(2): 367–76.  
PubMed Abstract | Publisher Full Text 
26. Martin SF, Dudda JC, Bachtanian E, et al.: Toll-like receptor and IL-12 signaling 
control susceptibility to contact hypersensitivity. J Exp Med. 2008; 205(9): 
2151–62.  
PubMed Abstract | Publisher Full Text | Free Full Text 
27. Esser PR, Wölfle U, Dürr C, et al.: Contact sensitizers induce skin inflammation 
via ROS production and hyaluronic acid degradation. PLoS One. 2012; 7(7): 
e41340.  
PubMed Abstract | Publisher Full Text | Free Full Text 
28.  Nakamura N, Tamagawa-Mineoka R, Ueta M, et al.: Toll-like receptor 3 
increases allergic and irritant contact dermatitis. J Invest Dermatol. 2015; 
135(2): 411–7.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
29. Pedersen LK, Johansen JD, Held E, et al.: Augmentation of skin response 
by exposure to a combination of allergens and irritants - a review. Contact 
Dermatitis. 2004; 50(5): 265–73.  
PubMed Abstract | Publisher Full Text 
30. Martin SF: Adaptation in the innate immune system and heterologous innate 
immunity. Cell Mol Life Sci. 2014; 71(21): 4115–30.  
PubMed Abstract | Publisher Full Text 
31. Bonefeld CM, Nielsen MM, Rubin IM, et al.: Enhanced sensitization and 
elicitation responses caused by mixtures of common fragrance allergens. 
Contact Dermatitis. 2011; 65(6): 336–42.  
PubMed Abstract | Publisher Full Text 
32. Bonefeld CM, Geisler C, Gimenéz-Arnau E, et al.: Immunological, chemical 
and clinical aspects of exposure to mixtures of contact allergens. Contact 
Dermatitis. 2017; 77(3): 133–42.  
PubMed Abstract | Publisher Full Text 
33. Koppes SA, Engebretsen KA, Agner T, et al.: Current knowledge on biomarkers 
for contact sensitization and allergic contact dermatitis. Contact Dermatitis. 
2017; 77(1): 1–16.  
PubMed Abstract | Publisher Full Text 
34.  Dhingra N, Shemer A, Correa da Rosa J, et al.: Molecular profiling of contact 
dermatitis skin identifies allergen-dependent differences in immune response. 
J Allergy Clin Immunol. 2014; 134(2): 362–72.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
35.  Quaranta M, Knapp B, Garzorz N, et al.: Intraindividual genome expression 
analysis reveals a specific molecular signature of psoriasis and eczema.  
Sci Transl Med. 2014; 6(244): 244ra90.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
36. Flier J, Boorsma DM, Bruynzeel DP, et al.: The CXCR3 activating chemokines 
IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test 
reactions. J Invest Dermatol. 1999; 113(4): 574–8.  
PubMed Abstract | Publisher Full Text 
37. Meller S, Lauerma AI, Kopp FM, et al.: Chemokine responses distinguish 
chemical-induced allergic from irritant skin inflammation: memory T cells 
make the difference. J Allergy Clin Immunol. 2007; 119(6): 1470–80.  
PubMed Abstract | Publisher Full Text 
38.  Garzorz-Stark N, Krause L, Lauffer F, et al.: A novel molecular disease 
classifier for psoriasis and eczema. Exp Dermatol. 2016; 25(10): 767–74.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
39.  Jakob A, Mussotter F, Ohnesorge S, et al.: Immunoproteomic identification 
and characterization of Ni2+-regulated proteins implicates Ni2+ in the induction 
of monocyte cell death. Cell Death Dis. 2017; 8(3): e2684.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
40. Schmidt M, Hupe M, Endres N, et al.: The contact allergen nickel sensitizes 
References F1000 recommended
Page 8 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
primary human endothelial cells and keratinocytes to TRAIL-mediated 
apoptosis. J Cell Mol Med. 2010; 14(6B): 1760–76.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41.  Mussotter F, Tomm JM, El Ali Z, et al.: Proteomics analysis of dendritic cell 
activation by contact allergens reveals possible biomarkers regulated by Nrf2. 
Toxicol Appl Pharmacol. 2016; 313: 170–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
42.  Zinkevičienė A, Kainov D, Lastauskienė E, et al.: Serum Biomarkers of 
Allergic Contact Dermatitis: A Pilot Study. Int Arch Allergy Immunol. 2015; 
168(3): 161–4. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
43. Koppes SA, Ljubojevic Hadzavdic S, Jakasa I, et al.: Stratum corneum profiles of 
inflammatory mediators in patch test reactions to common contact allergens 
and sodium lauryl sulfate. Br J Dermatol. 2017; 176(6): 1533–40.  
PubMed Abstract | Publisher Full Text 
44.  Mose KF, Burton M, Thomassen M, et al.: The gene expression and 
immunohistochemical time-course of diphenylcyclopropenone-induced 
contact allergy in healthy humans following repeated epicutaneous 
challenges. Exp Dermatol. 2017; 26(10): 926–33.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
45.  Molin S, Merl J, Dietrich KA, et al.: The hand eczema proteome: imbalance of 
epidermal barrier proteins. Br J Dermatol. 2015; 172(4): 994–1001.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
46.  Braun A, Dewert N, Brunnert F, et al.: Integrin αE(CD103) Is Involved in 
Regulatory T-Cell Function in Allergic Contact Hypersensitivity. J Invest 
Dermatol. 2015; 135(12): 2982–91.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
47.  Klein M, Bopp T: Cyclic AMP Represents a Crucial Component of Treg Cell-
Mediated Immune Regulation. Front Immunol. 2016; 7: 315.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
48.  Mahnke K, Useliene J, Ring S, et al.: Down-Regulation of CD62L Shedding 
in T Cells by CD39+ Regulatory T Cells Leads to Defective Sensitization in 
Contact Hypersensitivity Reactions. J Invest Dermatol. 2017; 137(1): 106–14.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
49. Weber FC, Esser PR, Müller T, et al.: Lack of the purinergic receptor P2X7 
results in resistance to contact hypersensitivity. J Exp Med. 2010; 207(12): 
2609–19.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50.  Neuberger A, Ring S, Silva-Vilches C, et al.: Expression of CD73 slows down 
migration of skin dendritic cells, affecting the sensitization phase of contact 
hypersensitivity reactions in mice. J Dermatol Sci. 2017; 87(3): 292–9.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
51.  Sun J, Madan R, Karp CL, et al.: Effector T cells control lung inflammation 
during acute influenza virus infection by producing IL-10. Nat Med. 2009; 15(3): 
277–84.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
52. Sun J, Cardani A, Sharma AK, et al.: Autocrine regulation of pulmonary 
inflammation by effector T-cell derived IL-10 during infection with respiratory 
syncytial virus. PLoS Pathog. 2011; 7(8): e1002173.  
PubMed Abstract | Publisher Full Text | Free Full Text 
53. Dolch A, Kunz S, Dorn B, et al.: Contact allergens induce CD8+ T cell-
derived interleukin 10 that appears dispensable for regulation of contact 
hypersensitivity. Exp Dermatol. 2017; 26(5): 449–51.  
PubMed Abstract | Publisher Full Text 
54.  Fjelbye J, Antvorskov JC, Buschard K, et al.: CD1d knockout mice exhibit 
aggravated contact hypersensitivity responses due to reduced interleukin-10 
production predominantly by regulatory B cells. Exp Dermatol. 2015; 24(11): 
853–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
55.  Gomez de Agüero M, Vocanson M, Hacini-Rachinel F, et al.: Langerhans cells 
protect from allergic contact dermatitis in mice by tolerizing CD8+ T cells and 
activating Foxp3+ regulatory T cells. J Clin Invest. 2012; 122(5): 1700–11.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
56. Luckey U, Schmidt T, Pfender N, et al.: Crosstalk of regulatory T cells and 
tolerogenic dendritic cells prevents contact allergy in subjects with low zone 
tolerance. J Allergy Clin Immunol. 2012; 130(3): 781–797.e11.  
PubMed Abstract | Publisher Full Text 
57.  Hacini-Rachinel F, Gomez de Agüero M, Kanjarawi R, et al.: Intestinal 
dendritic cell licensing through Toll-like receptor 4 is required for oral 
tolerance in allergic contact dermatitis. J Allergy Clin Immunol. 2018; 141(1): 
163–70.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
58. El Beidaq A, Link CW, Hofmann K, et al.: In Vivo Expansion of Endogenous 
Regulatory T Cell Populations Induces Long-Term Suppression of Contact 
Hypersensitivity. J Immunol. 2016; 197(5): 1567–76.  
PubMed Abstract | Publisher Full Text 
59.  Di Gioacchino M, Ricciardi L, De Pità O, et al.: Nickel oral hyposensitization 
in patients with systemic nickel allergy syndrome. Ann Med. 2014; 46(1): 31–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
60.  Christoffers WA, Blömeke B, Coenraads PJ, et al.: The optimal patch test 
concentration for ascaridole as a sensitizing component of tea tree oil. Contact 
Dermatitis. 2014; 71(3): 129–37.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
61.  Chaudhry HM, Drage LA, El-Azhary RA, et al.: Delayed Patch-Test Reading 
After 5 Days: An Update From the Mayo Clinic Contact Dermatitis Group. 
Dermatitis. 2017; 28(4): 253–60.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
62. Joy NM, Rice KR, Atwater AR: Stability of patch test allergens. Dermatitis. 2013; 
24(5): 227–36.  
PubMed Abstract | Publisher Full Text 
63. Johansen JD, Aalto-Korte K, Agner T, et al.: European Society of Contact 
Dermatitis guideline for diagnostic patch testing - recommendations on best 
practice. Contact Dermatitis. 2015; 73(4): 195–221.  
PubMed Abstract | Publisher Full Text 
64.  Engfeldt M, Hagvall L, Isaksson M, et al.: Patch testing with hydroxyisohexyl 
3-cyclohexene carboxaldehyde (HICC) - a multicentre study of the Swedish 
Contact Dermatitis Research Group. Contact Dermatitis. 2017; 76(1): 34–9. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
65. Uter W, Bruze M, Rustemeyer T, et al.: Re “International survey on skin patch 
test procedures, attitudes and interpretation” L.K. Tanno et al., WAOJ (2016) 
9:8. World Allergy Organ J. 2017; 10(1): 18.  
PubMed Abstract | Publisher Full Text | Free Full Text 
66. Kim N, Notik S, Gottlieb AB, et al.: Patch test results in psoriasis patients on 
biologics. Dermatitis. 2014; 25(4): 182–90.  
PubMed Abstract | Publisher Full Text 
67. Wee JS, White JM, McFadden JP, et al.: Patch testing in patients treated with 
systemic immunosuppression and cytokine inhibitors. Contact Dermatitis. 
2010; 62(3): 165–9.  
PubMed Abstract | Publisher Full Text 
Page 9 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
 Open Peer Review
   Current Peer Review Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the reviewers
provide input before publication and only the final, revised version is published. The reviewers who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The reviewers who approved this article are:
Version 1
 Bruce Brod
Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA
 No competing interests were disclosed.Competing Interests:
1
 Donald V. Belsito
Department of Dermatology, Columbia University Medical Center, New York, NY, USA
 No competing interests were disclosed.Competing Interests:
2
 Ann-Therese Karlberg
Dermatochemistry and Skin Allergy, Department of Chemistry and Molecular Biology, University of
Gothenburg, Gothenburg, Sweden
 No competing interests were disclosed.Competing Interests:
3
Page 10 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
 The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
Page 11 of 11
F1000Research 2018, 7(F1000 Faculty Rev):810 Last updated: 17 MAY 2019
